Several agents have proven to be effective for PJP prophylaxis, trimethoprim-sulfamethoxazole (TMP-SMX), dapsone, atovaquone and IV or aerosolized pentamidine. 4, 5 The current guidelines for PJP prophylaxis in the setting of allo-HSCT recommend TMP-SMX; 6 however, this agent is associated with myelosuppressive effects, which can delay engraftment 7, 8 and hepatotoxicity. Given these adverse effects, issues of adherence with oral PJP prophylaxis and data showing tolerability and efficacy of IV pentamidine in children diagnosed with HIV, 4,9 the division of HSCT at the Ann and Robert H Lurie Children's Hospital (formerly Children's Memorial Hospital) implemented the use of IV pentamidine as a first-line agent for PJP prophylaxis in patients undergoing HSCT. We reviewed this experience to determine the rate of breakthrough PJP while on IV pentamidine, and to assess the adverse effects and tolerability of IV pentamidine in allo-HSCT recipients.
We analyzed the infusion-related adverse effects of IV pentamidine used for PJP prophylaxis in pediatric patients undergoing first allo-HSCT between January 2007 and December 2012. The study was approved by the hospital's institutional review board. Patient information collected included age, sex, diagnosis before allo-HSCT, development of acute and chronic GvHD, number of IV pentamidine doses administered, interval between doses and incidence of PJP. IV pentamidine was administered as one dose (4 mg/kg/dose) before HSCT followed by one dose every 4 weeks until stable engraftment greater than 100 days post HSCT. Infusions were given over 2 h through indwelling central venous catheters or by peripheral IV. In order to assess efficacy, we excluded patients who received the drug at intervals 46 weeks, who received o 3 doses or who received alternative PJP prophylaxis agents.
Of 193 allo-HSCTs performed during the study period, we excluded 14 patients who received o 3 doses of IV pentamidine (doses not limited due to toxicity), 5 patients who received IV pentamidine doses 46 weeks apart, 4 who received an alternative PJP prophylaxis agent, 14 patients with prior HSCT and 12 patients 418 years old. As a result, there were 142 evaluable patients included. The characteristics of our cohort are described in Table 1 . The median age at the time of allo-HSCT was 7.59 years (range: 0.08-17.87 years). Hematologic malignancy was the major indication for allo-HSCT and the majority of patients received peripheral blood as their stem cell source. Forty-eight patients (34%) were diagnosed with grade 2-4 acute GvHD, but 40 patients were eventually diagnosed with limited or extensive chronic GvHD.
A median of 6 doses (range 3-56 doses) of IV pentamidine were administered. Reflecting a longer duration of immune suppression, patients who developed extensive chronic GvHD received an average of 18 doses of pentamidine prophylaxis compared with 7 doses for those who did not develop extensive chronic GvHD. There were no cases of PJP documented during the study period. Although excluded from toxicity assessments, patients who received 2 or fewer doses of IV pentamidine or doses greater than 6 weeks between prophylaxis treatments did not develop PJP or die of respiratory failure of unknown origin. Infusion-related side effects of IV pentamidine by system in the 142 patients included in this report (see Table 2 ) were characterized as: neurologic (n = 10, 29%), respiratory (n = 7, 21%), gastrointestinal (n = 4, 12%), cardiovascular (n = 2, 6%) or dermatologic (n = 5, 15%). The specific grades were not reported in our patient population. The neurologic symptoms reported were paresthesia (n = 6), headache (n = 2), agitation (n = 1) and lightheadedness (n = 1). The upper respiratory and airway symptoms included nasal congestion (n = 2), cough (n = 2), dyspnea (n = 2) and throat itchiness (n = 1). Cardiovascular symptoms were rare; one patient experienced hypertension and one experienced hypotension, which were controlled with one dose of labetalol and slowing down the infusion rate, respectively. Symptoms of nausea (n = 2) and vomiting (n = 2) were reported. Dermatologic symptoms included lip swelling (n = 1), hives (n = 2), flushing (n = 1) and a non-specified rash (n = 1). Most patients with adverse effects were later pre-medicated with diphenhydramine, acetaminophen, ondansetron and/or lorazepam depending on the symptom. Importantly, no patient discontinued therapy secondary to any adverse effect. However, a limitation of our results is the possibility of having overlooked some adverse effects during retrospective data collection.
Current guidelines recommend the use of oral TMP-SMX as an initial prophylaxis agent for PJP infection. 6, 10 Despite its success, low cost and superior efficacy over other commonly used agents such as dapsone or atovaquone, 1, 6, 10 the adverse effects associated with TMP-SMX, in particular myelosuppression 7, 8 and potential delay in engraftment, 6, 8 make it a less desirable agent for use in the peri-transplantation setting. Ena et al. 9 reported IV pentamidine as efficacious in HIV patients, with no breakthrough cases in the 37 HIV patients who received IV pentamidine prophylaxis. These reports, combined with our institution's experience of increased patient adherence to IV therapy, led to the implementation of IV pentamidine as a first-line agent for PJP prophylaxis in patients undergoing HSCT at our institution. Although TMP-SMX could also provide prophylaxis for toxoplasmosis, we found no cases of breakthrough of toxoplasmosis in the absence of TMP-SMX.
Our study shows no breakthrough PJP infection in post-HSCT patients receiving IV pentamidine prophylaxis, consistent with the findings of other pediatric HSCT 7,10,11 cohorts. Kim et al. 7 reported only one case of breakthrough PJP that occurred in 79 patients who underwent allo-HSCT. The single case of PJP occurred after a second allo-HSCT. They reported no cases of breakthrough PJP in patients undergoing first allo-HSCT. Similarly Clark et al. 10 found no cases of breakthrough PJP among patients who underwent first allo-HSCT, but one case of PJP infection occurred following a second HSCT. DeMasi et al.
11 also retrospectively reviewed 137 pediatric HSCT recipients (54 allogeneic) who received IV pentamidine and found no cases of breakthrough PJP.
Our findings regarding adverse events associated with IV pentamidine are also consistent with previous studies. Yeung et al. 12 reported side effects as common but mild in patients with HIV, and DeMasi et al. 11 deemed IV pentamidine to be safe in their pediatric HSCT cohort. Recently, Lim et al. 13 reported a retrospective review of adult allo-HSCT recipients receiving IV pentamidine for primary prophylaxis of PJP. They also reported no breakthrough PJP infections, good tolerance and certainty of compliance.
This was a retrospective analysis that did not include a randomized comparison arm with alternative PJP prophylaxis. However, a prospective study comparing IV pentamidine with TMP-SMX would be difficult, as TMP-SMX is anticipated to have more variability in tolerability and adherence due to cytopenias. The low rate of breakthrough infections with either method of prophylaxis would require large patient numbers in each arm of a randomized study to determine superiority or equivalence.
In conclusion, our study shows that IV pentamidine appears to be effective for prevention of PJP infection in first allo-HSCT as there were no documented cases of breakthrough infection in our cohort. Despite adverse effects of the IV infusion being common, they were well tolerated and no patient discontinued therapy because of toxicity. Overall, adherence to therapy was high, with only five patients excluded for receiving IV pentamidine 46 weeks apart. On the basis of our data, IV pentamidine may be considered as an alternative to TMP-SMX for prophylaxis of PJP in pediatric patients undergoing first allo-HSCT. Incidence of PJP 0 0
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